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Merkel Cell Polyomavirus in Cutaneous Squamous
Cell Carcinoma of Immunocompetent Individuals
Amy M. Dworkin1, Stephanie Y. Tseng2, Dawn C. Allain3,4,5, O. Hans Iwenofu6, Sara B. Peters6 and
Amanda E. Toland4,7
Squamous cell carcinoma (SCC) is the second most frequently diagnosed skin cancer. It has a higher incidence in
immunosuppressed individuals such as organ transplant recipients and human immunodeficiency virus (HIV)
carriers. Recently, a newly described polyoma virus, Merkel cell polyomavirus (MCPyV), was found in Merkel cell
carcinoma (MCC), a rare aggressive skin cancer also associated with immunosuppression. We hypothesized that
MCPyV would be present in SCCs. To test for the presence of MCPyV in immunocompetent SCC patients, we
used PCR primer sets directed against the large T (LT) antigen and VP1 gene of MCPyV. We detected MCPyV in
15% (26/177) of SCC DNA samples and 17% (11/63) of adjacent skin DNA samples from 21 of 58 (36%) individuals
studied. We did not detect MCPyV in any matched normal blood DNA (0/57), but observed the presence of
MCPyV DNA in 1 of 12 normal mouthwash DNAs. All sequenced SCC samples had a common mutation truncating
the LT antigen that provides indirect evidence of viral integration. The presence of MCPyV inB15% of SCCs from
immunocompetent individuals warrants evaluation of MCPyV as an etiologic agent in the carcinogenesis of SCC.
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INTRODUCTION
Non-melanoma skin cancers, including basal cell carcinoma
and squamous cell carcinoma (SCC), are the most frequently
diagnosed tumors. Their incidence continues to increase
worldwide (Boukamp, 2005). SCC is the second most
common skin cancer with over 200,000 cases diagnosed in
the United States each year. Risk factors leading to SCC
development include immunosuppression, UV light, soot,
arsenic ingestion, and burns (Boukamp, 2005). Viruses, such
as human papilloma virus (HPV), have also been suggested to
have a causal role in cutaneous SCC (Hengge, 2008). Recent
studies have searched for the presence of a newly described
polyomavirus, the Merkel cell polyomavirus (MCPyV), in
SCC cases (Kassem et al., 2009).
Polyomaviruses can be divided into three subgroups:
avian, mammalian related to murine polyomavirus (MuPyV),
and mammalian related to SV40. In 2008, Feng et al. (2008)
discovered a new polyomavirus, MCPyV, which occurs in a
rare human cancer, Merkel cell carcinoma (MCC), and can
integrate into cellular DNA. Before the discovery of MCPyV,
all the known human polyomaviruses, such as BKV, JCV, KIV,
and WUV, belonged to the mammalian related to the SV40
group. The recently discovered MCPyV shows close homo-
logy to the mammalian related to the MuPyV subgroup.
Owing to their ability to immortalize cells and cause
cancer in animal models, polyomaviruses have been studied
extensively for their role in tumorigenesis (zur Hausen, 2008).
MCC, a rare neuroendocrine tumor of the skin, is observed in
the elderly and immunosuppressed patients such as organ
transplant recipients, chronic lymphocytic leukemia patients,
and acquired immune deficiency syndrome patients (Heath
et al., 2008). MCPyV has been detected in 77–84% of MCC
tumors, but its potential contribution to MCC development is
unknown (Feng et al., 2008; Kassem et al., 2008; Viscidi and
Shah, 2008; Becker et al., 2009). MCPyV in SCC has been
identified in 52% of SCCs from immunocompromised indivi-
duals and in 25% of SCCs from immunocompetent patients
(Kassem et al., 2009). The aim of this study was to determine
whether MCPyV was present in SCC and other tissues from
immunocompetent patients in a large patient cohort.
RESULTS
MCPyV detection in SCCs and matched normal samples
On the basis of previous studies showing the presence of
MCPyV in MCC samples, we hypothesized that the MCPyV
would be present in SCCs of immunocompetent individuals.
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In total, 21 of 58 (36%) individuals with SCC had one or more
samples test positive for the MCPyV. These samples included
1 of 58 normal DNAs, 26 of 177 SCCs, and 11 of 63 adjacent
skin samples (Table 1; Figure 1a and Supplementary
Table 1. Summary of all study samples
Individual Sex
Age at
first SCC
(years)
SCC
samples
SCCs
VP1/
LT3
Adjacent
skin
samples
Adjacent
skin
VP1/LT3
111137 M 71 1  1 
1 + 
112866 M 78 5  2 
116965 M 69 1  NA NA
117185 M 82 6  4 
1 +
120547 F 73 4  NA NA
121885 M 80 1  NA NA
124229 M 55 3  1 
124385 F 71 1  1 
124386 M 72 1 + 1 
124387 M 62 5  6 
1 +
126165 M 54 2  NA NA
126286 M 63 1  1 
128645 M 60 2 + NA NA
130785 F 56 5  1 
2 + 1 +
142585 M 72 6  4 
2 + NA NA
144345 M 66 1 
2 + 1 +
144365 M 59 2  NA NA
146045 F 43 1  1 
149827 M 70 1  2 
1 + NA NA
153065 M 88 1 + 1 +
153706 M 67 1 + NA NA
154107 F 59 2  NA NA
154108 M 77 1  NA NA
154566 M 53 1  1 
155092 M 40 1  NA NA
3 + 2 +
155112 M 75 1  1 
158251 M 56 6  1 
1 +
159438 F 59 3  4 
1 + 1 +
163489 M 83 1  1 
Table 1. Continued
Individual Sex
Age at
first SCC
(years)
SCC
samples
SCCs
VP1/
LT3
Adjacent
skin
samples
Adjacent
skin
VP1/LT3
166849 M 69 1  1 
169773 F 55 1  NA NA
173542 M 40 1  NA NA
176171 M 69 1  1 
176172 M 60 1  1 
1 +
1785421 M 83 2  NA NA
199527 M UA 1  NA NA
26143 F 67 1  NA NA
27263 M 75 2  NA NA
27622 M 57 8  NA NA
28646 M 84 3  NA NA
29003 F 53 1  NA NA
29082 M 73 0 NA NA NA
29564 M 70 4  NA NA
29942 M 80 2  NA NA
30582 F 69 1  NA NA
30606 M 55 14  1 
30742 F 80 1 + NA NA
32183 M 71 1  NA NA
32782 M 76 27  3 
1 + 1 +
34562 M 68 4  2 
35243 F 78 2  1 
35422 F 48 1 + NA NA
35462 F 44 1  2 
36882 M 76 3  2 
37022 M 56 7  4 
38463 M 55 1  NA NA
57565 M 65 1 + 1 +
69612 F 58 2 + 2 +
80306 F 53 1  NA NA
Postive patients 21 (36%)
Negative patients 37 (64%)
Total patients 58
Negative
samples
151 (85%) 52 (83%)
Positive samples 26 (14%) 11 (17%)
Total samples 177 63
F, female; M, male; NA, nonapplicable; +, positive for virus; , negative
for virus; SCC, squamous cell carcinoma; UA, unavailable.
1Positive for virus in mouthwash genomic DNA.
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Table S1) In our initial studies using published primer sets for
both the large-T antigen (LT)3 and VP1 MCPyV primers (Feng
et al., 2008), 19 of 177 SCCs and 11 of 63 adjacent skin
samples from 58 individuals were positive for one or more
primer sets (Figure 1a). To obtain higher detection sensitivity,
we analyzed 14 samples that were positive for only one
primer set and 22 samples that were negative for both primer
sets by radioactive PCR. All 14 samples that were positive for
one primer set initially were positive by radioactive PCR for
both primer sets, whereas none of the samples negative by
PCR by both primer sets were positive by radioactive PCR
(0/22; Figure 1b). As another means of increasing our
detection sensitivity, we tested 21 samples that were negative
for both primer sets at higher DNA input concentrations
(50 ng). Of 22 samples, 7 (31%) that were negative by PCR at
15 ng input were positive at the higher input. No samples that
were negative by radioactive PCR (0/5) were positive at the
higher DNA input concentrations. At the end of these
experiments, we had 100% concordance of calls of duplicate
samples (47/47). No blood genomic DNA (0/57) tested
positive by MCPyV DNA PCR; however, one normal
mouthwash genomic DNA sample (1/1) from an SCC patient
tested positive. In summary, 1.7% of normal control DNAs,
15% of SCCs, and 17% of adjacent skin samples from 21 of
58 individuals tested positive for MCPyV by PCR.
We hypothesized that individuals with one tumor positive
for MCPyV would be more likely to have other SCCs positive
for MCPyV. To test this hypothesis, we compared PCR results
of the SCCs from 31 individuals who had more than one
tumor analyzed for the presence of MCPyV. Of 31 patients, 6
(19%) with multiple tumors had more than one tumor
positive for MCPyV (Table 1). Thus, within an individual,
we observed variability in MCPyV positivity. We next
correlated the results of viral status between normal adjacent
and SCC DNAs in 32 patients for whom both types of samples
were tested. From these patients, we had 46 pairs of matched
tumor/adjacent skin samples (Supplementary Table S1). Of
these, 33 pairs were negative for the presence of MCPyV in
both tumor and adjacent skin samples, 6 were positive for
only the tumor, and 7 were positive for both. Of the 46 paired
sample sets, we had correlation for detection of the virus of
87% (Figure 2 and Supplementary Table S1).
MCPyV detection in mouthwash DNA samples
Initially, we tested one normal mouthwash DNA sample from
an SCC patient for the presence of MCPyV. After this sample
was found to contain MCPyV DNA, we tested 11 additional
mouthwash DNA samples from individuals with non-oral,
non-skin cancers to determine whether this was an unusual
finding or whether MCPyV was present at a high frequency in
apparently normal oral mucosa. Of the 12 total samples
tested, only the initial sample tested positive for the virus,
indicating that MCPyV is not found at a high frequency in
normal oral muscosa.
The role of immunosuppression in MCPyV infectivity
As MCC is a disease of the elderly, which may correlate with
decreased immune function in aging populations (Swann and
Yoon, 2007), we wanted to determine whether the presence
of MCPyV in SCC correlated with age of first SCC
development. In our study population, the average age of
SCC diagnosis in patients testing negative for MCPyV was
71 years (SD±38) and the average age of SCC diagnosis in
patients testing positive for MCPyV was 65 years (SD±10).
Of 42 male patients, 16 (38%) and of 16 female patients 5
(31%) tested positive for MCPyV. On the basis of these data,
no definitive conclusions can be made regarding the role of
age or gender in infection (Table 1).
All the samples included in the analysis were from
individuals believed to have functioning immune systems.
To determine whether individuals were taking medications
that might depress their immune system, we analyzed the
medical records and questionnaire information from a
majority of study participants. Five individuals had a
confirmed history of long-term use of medications that are
known or suspected to affect the immune system. One of
these individuals took Prednisone over a 13-year period and
had no tumors test positive for MCPyV. The other four
individuals all had tumors that tested positive for the
polyomavirus. Two of these individuals had their SCC
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Figure 1. MCPyV detection. (a) The presence of MCPyV in SCCs, genomic
normal DNA, and adjacent skin DNA was determined by PCR using VP1
primers. A representational result is shown with 6 of 16 samples tested
showing a PCR product at 351 bp. All experiments included DNA from an
MCPyV plasmid as a positive control (P) and a negative water control (W).
M, molecular weight marker; þ , positive for virus; , negative for virus. (b)
To increase sensitivity for detection of the MCPyV virus, radioactive PCR was
conducted using VP1 primers. Samples include those that were positive for
the LT3 primer set and negative for the VP1 primer set by regular PCR. All
samples that were positive by one of the two primer sets by regular PCR were
positive for the other primer set by radioactive PCR. Shown is a
representational experiment that also includes 2 of 22 samples that were
negative for both LT3 and VP1 primer sets by regular PCR. These were also
negative by radioactive PCR. W, water control; þ , positive for MCPyV;
, samples negative for MCPyV, and P, positive plasmid control.
M W G T T A P W G T T A P
V L
Figure 2. MCPyV detection in multiple samples from a single individual.
Multiple samples including two SCCs, one adjacent skin DNA, and normal blood
DNA from a single individual were amplified using MCPyV primers LT3 (308bp)
and VP1 (351bp). Results show that both SCCs and the adjacent skin DNA
samples tested positive for the presence of MCPyV on both primer sets, whereas
the normal blood DNA was negative for the presence of the virus. M, molecular
weight marker; W, water control; G, genomic normal DNA; T, SCC DNA; A,
adjacent skin DNA; P, positive control; L, LT3 primer set; V, VP1 primer set.
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diagnosed before the documented onset of immunosuppres-
sive drugs, and thus their SCC diagnosis is not related to the
use of these medications. Of the two other individuals, one
took hydrocortisone for 3 months before the diagnosis of the
MCPyV-positive tumor, and the second individual with two
SCCs with MCPyV took Aldara (Graceway Pharmaceuticals,
Bristol, TN) and Soriatane (Stiefel Laboratories, Coral Gables,
FL) for at least a year before the time of diagnosis. These
numbers are too small to reach any conclusions. However, it
is interesting that of the 21 individuals who tested positive for
polyomavirus, 2 (9%) were taking drugs affecting the immune
system, whereas only 1 of 37 (2.7%) individuals who tested
negative for MCPyV reported any long-term use of immuno-
suppressive agents.
HPV status
As HPV is postulated to have a role in SCC development and
MCPyV is hypothesized to be important for the development
of MCC, we speculated that if the MCC virus were having a
role in SCC tumorigenesis, SCCs positive for MCPyV would
be less likely to be positive for HPV. We tested 30 MCPyV-
positive samples from 16 patients for the presence of HPV
using HPV primer sets that detect over 25 HPV strains
(Husnjak et al., 2000). In total, 20 of 30 (66%) polyomavirus-
positive samples from 14 of 16 (87%) individuals tested
positive for HPV. We compared these data with those from
21 MCPyV-negative samples from seven patients to deter-
mine whether the rates of HPV infection were similar in our
sample sets. Of 21 samples, 9 (42%) from 4 of 7 (57%)
MCPyV virus-negative patients tested positive for HPV.
MCPyV sequence analysis
A study by Shuda et al. (2008) showed that MCPyV T antigens
derived from MCC acquire mutations ablating full-length LT
expression and MCPyV replication capacity. To determine
whether there were any VP1, LT, small T, or protein-binding
domain mutations present in the samples containing MCPyV,
we sequenced 31 positive samples. Not all samples were
sequenced for all seven MCPyV primer sets because of
insufficient DNA amounts or difficulty in amplifying specific
regions, possibly because of mutations located at the sites of
the primers. In total, 26 unique nucleotide changes were
observed: 6 synonymous amino-acid changes, 17 non-
synonymous amino-acid changes, 1 stop codon, and 2
changes of unknown significance (Table 2; Supplementary
Table S2). The number of mutations per sample ranged from
1 to 10 substitutions in the regions sequenced (Supplemen-
tary Table S2). All samples except three adjacent skin samples
and one mouthwash sample were found to have a common
mutation at nucleotide 1401 (G14014T) in exon 2, leading
to a premature truncation in the LT helicase. In one paired
normal adjacent/tumor sample set, the normal adjacent
sample did not have the truncating mutation found in the
tumor sample. This suggests that the mutation occurred post
infection. The mouthwash sample contained no non-synon-
ymous changes. The CR1, DNAJ and Rb-binding domains did
not contain any non-synonymous or truncating mutations in
any of the samples sequenced.
DISCUSSION
The recently identified MCPyV is the first human polyoma-
virus that shows clonal integration in a human malignant
tumor (Feng et al., 2008). The finding of MCPyV inB80% of
human MCCs suggests a role of this virus in the carcinogen-
esis of MCC (Feng et al., 2008; Kassem et al., 2008). The goal
of this study was to test another malignant tumor of the skin,
SCC, for the presence of MCPyV. Two large studies have
looked for MCPyV in SCCs from immuncompromised organ
transplant recipients. In one study, only 1 of 156 skin lesions
was positive, whereas in the other study 52% of 56 SCCs
were positive (Kassem et al., 2009; Ridd et al., 2009). Kassem
et al. also looked for the presence of MCPyV in SCCs
from immunocompetent individuals and found that 25%
(7/28) of SCCs showed evidence of the virus. We detected
MCPyV in 15% of SCCs. Our results are consistent with a
study in which 15 SCCs were tested for MCPyV and 2 tumors
(13%) were positive for the polyomavirus (Garneski et al.,
2009). In the Garneski and Kassem studies, MCPyV was
not detected in any of the normal skin samples. This differs
from our results, in which we detected MCPyV in 17% of
adjacent skin samples. It is possible that our normal
adjacent samples, although histologically normal, were close
enough to the tumor sites to house the virus and that the
normal skin samples analyzed in the other studies were
outside of a field of pre-malignant changes. The differences in
detection rate between the studies and tissue types may be
because of the differences in sensitivity for detection of
different viral loads.
We may be underestimating the frequency of SCCs that
are positive for the MCC virus. Initially, we tested 240 skin
samples using 15 ng of input DNA, for which 14% were
positive for one or more primers. We used two additional
strategies for detection of virus in samples that were negative
for both primer sets: radioactive PCR and higher input DNA
(50 ng). We did not detect any additional positive samples (0/
22) by radioactive PCR. However, using a higher input of
DNA, 7 of 22 (32%) samples were positive. Five samples
were tested by both methods; none of these were positive for
the virus. These data suggest that the virus may be present in
as many as 32% of samples and that we may be missing the
virus in a subset of samples. These data also suggest that there
may be differences in viral load between samples as samples
with higher viral load may be more likely to test positive at
lower DNA inputs.
In this study, multiple SCCs and matched normal samples
from individuals were tested for the presence of MCPyV. We
found an 87% concordance for the presence of MCPyV in 46
sets of matched SCC and adjacent skin samples (40/46).
These data suggest a field effect of infection. We also showed
that 6 of 31 (19%) individuals with multiple SCCs had more
than one SCC test positive. These results are interesting, in
that not all tumors arising in individuals with MCPyV are
positive for the virus. This either suggests that there is no
systemic effect of the virus or that we are not detecting the
presence of the virus in some samples. Also interesting are
two patients with large numbers of SCCs in which 0 of 14 and
1 of 28 tumors tested positive for the presence of the virus.
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Although apparently normal skin samples can test positive for
the polyomavirus, we, similar to other studies, did not
identify any blood DNAs that were positive (Feng et al., 2008;
Kassem et al., 2008).
Our results suggest that the polyomavirus may be present
in apparently normal epithelial tissues. Consistent with this
finding is that 1 of 12 normal mouthwash DNAs was positive
for MCPyV. It is difficult to say from this study whether we are
detecting the background rate of MCPyV infection of
approximately 10–15% of samples or whether there is a link
between the polyomavirus and the development of SCC.
Although we cannot rule out a similar frequency of infection
in individuals with no SCCs, previous studies assessing nine
normal skin samples isolated from surgical patients observed
no evidence of MCPyV (Feng et al., 2008). Other studies have
looked for MCPyV in non-skin tissues. Feng et al. (2008)
found MCPyV in a small subset of control samples including
the small bowel, hemorrhoids, appendix, and gall bladder.
Another study looked for the presence of MCPyV in
cancerous prostate epithelia, matched benign epithelia, and
tumor-adjacent samples and found no evidence of the virus
(Bluemn et al., 2009). Two studies have examined
nasopharyngeal aspirate samples for the presence of MCPyV
and had detection rates of 1.3–4.3% (Bialasiewicz et al.,
2009; Goh et al., 2009). Sastre-Garau et al. (2009) failed to
detect MCPyV in 1,241 non-MCC tumor specimens of
various types.
Previous studies for viral infectivity in cutaneous SCCs
have focused on HPV. We tested for HPV status in MCPyV-
positive and MCPyV-negative samples from 23 individuals.
Although the overall rate of samples with detectable HPV was
similar between the groups (66 versus 42%), there was a
higher proportion of individuals in the MCPyV-positive group
(87%) than the MCPyV-negative group (57%), which had one
or more samples test positive for HPV. From these data, we
are unable to establish a clear correlation between MCPyV
and HPV infectivity. Our data are consistent with previous
studies reporting that 30–92% of SCCs are positive for the
presence of HPV (Berkhout et al., 1995; Hopfl et al., 1997;
Pfister, 2003).
Table 2. Nucleotide substitutions detected by sequencing
EU375804 position Large T Small T vp1 Mouthwash Normal adjacent SCC Positive control1
c234g leu13leu leu13leu 1/1 0/9 1/14 1/1
a246g leu17leu leu17leu 1/1 0/9 0/14 0/1
a622g thr143ala 0/1 0/9 1/14 0/1
t659c leu155pro 0/1 1/9 2/15 1/1
g718a glu175lys 0/1 1/10 1/17 0/1
a793g 0/1 2/10 1/18 0/1
c843g 1/1 1/10 0/18 1/1
g1242t asp207tyr 0/1 0/10 7/18 0/1
c1360g ser246cys 0/1 0/10 7/18 1/1
t1383c ser263pro 0/1 0/10 1/18 0/1
g1401t glu259stop 0/1 7/10 19/19 1/1
g1411t arg263ile 0/1 0/10 1/19 1/1
a1428c thr269pro 0/1 4/10 4/19 0/1
c1534t pro304leu 0/1 3/4 4/8 0/1
g1541c lys306asn 0/1 1/4 1/8 1/1
g1566a asp315asn 0/1 0/4 1/8 1/1
a1575g ile318val 0/1 2/4 4/8 1/1
c1581g leu321val 0/1 0/4 1/8 1/1
c1771t ser383phe 0/1 1/4 1/8 1/1
c3634t leu201leu 0/1 1/2 7/9 1/1
g3691a tyr182tyr 1/1 0/2 0/9 0/1
t3709c gln176gln 0/1 0/2 4/9 0/1
c3712t leu175leu 1/1 0/2 0/9 1/1
t3725c glu171gly 0/1 0/2 1/9 0/1
t3797c lys147arg 0/1 0/2 1/9 0/1
c3943a leu108phe 0/1 0/2 1/9 0/1
SCC, squamous cell carcinoma.
1Mutations observed only in the positive control sample are not reported.
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We sequenced portions of the MCPyV LT and VP1 genes.
All but four of the MCPyV-positive samples shared a common
mutation ablating full-length LT expression, which may
abolish replication capacity. These results are intriguing in
the context of the findings of Shuda et al. (2008), whose
results suggested that truncating mutations in LT in tumors are
not an experimental artifact but are a general feature of
polyomavirus-mediated carcinogenesis. Their data suggest
that MCPyV-associated MCC is a two-step process: first with
viral genome integration followed by LT antigen mutation to
prevent autonomous viral genome replication. Full-length LT
is important for virus replication and cell lysis. Intact LT could
also lead to DNA damage response or immune recognition
hindering new tumor cell survival. The samples with intact LT
antigen include the normal mouthwash sample and three
normal adjacent skin samples, whereas all the tumors
and the majority of adjacent skin samples had the truncated
version. It remains to be seen whether the skin samples
with truncating mutations show integration of the virus;
this is an important question on which to follow up.
As we did not sequence the complete MCPyV genome, it is
possible that we missed other truncating mutations in these
samples. Nonetheless, truncating mutations may serve as
markers to distinguish tumorigenic versus non-tumorigenic
MCPyV viruses. MCPyV has conserved features of other
polyomaviruses including the CR1, DNAJ, and Rb-binding
domains. These regions were intact in all of our sequenced
MCPyV-positive samples and are thus predicted to be
functional.
The majority of samples testing positive in our series
contained unique sequence alterations, reducing the like-
lihood of PCR contamination. There were shared mutations
in MCPyV-positive samples and the polyomavirus DNA was
used as a positive control (MCC350). However, no sample
matched the control in its entirety. Interestingly, the single
truncating mutation observed in this study was identical to
the one found in MCC350; however, the same amplicon in
which the truncating mutation was observed had a
number of sequence differences between MCC350 and other
positive samples. We do not know the biological relevance
of a common truncating mutation found in SCCs or if our
results are because of some experimental artifact. None-
theless, these results are intriguing, as MCCs are reported to
have many different truncating mutations. These data may
suggest a different mechanism of action between the tumor
types.
We sequenced four tumor and normal adjacent matched
sets and five pairs of independent tumors from the same
person. Three of the four tumor/normal pairs and three
of the five tumor/tumor pairs showed the exact nucleotide
substitutions for sequenced regions. The remaining tumor/
normal pair shared three of nine sequence changes and the
two other tumor/tumor pairs shared one of the two and one of
the seven changes, respectively. Combining the data, about
half of the changes seen in multiple samples from an
individual are shared, suggesting that individuals may either
be infected with a single virus at various sites and that
additional mutations occur subsequently or they
may be infected multiple times with different versions of
the virus.
Results from this study show that MCPyV is found in SCCs
arising in immunocompetent individuals and there is indirect
evidence consistent with genomic integration in tumors and
normally appearing skin. In our study, 36% of individuals had
one or more samples test positive for the presence of MCPyV,
indicating that the frequency of infectivity in the immuno-
competent population may be higher than initially suspected.
Despite the relatively low frequency of positivity in SCCs
overall (15%), the pathogenic relevance of polyomavirus in
SCC is unknown and warrants investigation.
MATERIALS AND METHODS
Patients and tissues
This study was approved by The Ohio State University (OSU) Cancer
Institutional Review Board according to the Declaration of Helsinki
Principles. All study participants signed informed consent. Patients
were ascertained through OSU Medical Center dermatology clinics.
Study criteria included a source of normal genomic DNA (blood,
mouthwash, or saliva), available tissue from at least one SCC, a
questionnaire on sun exposures and other medical history, and a
signed medical record release form. Tissue samples included 240
formalin-fixed and paraffin-embedded biopsy specimens, 57 blood
specimens, and 1 normal mouthwash specimen from a total of 58
individuals. Eleven additional mouthwash samples were obtained
from individuals with other cancers to determine the presence of the
polyomavirus in DNA from oral mucosa. Hematoxylin and eosin
slides from tumors were reviewed by two pathologists, and areas
comprising470% of tumor cells were microdissected or cored from
tumor blocks. Cores were also obtained from formalin-fixed and
paraffin-embedded histologically normal adjacent skin when available.
Genomic DNA from normal adjacent tissue and SCCs was
isolated from fixed archival tissue by the removal of paraffin using
xylene and ethanol washes. Protein was removed by proteinase K
treatment for 48 hours at 55 1C in nucleic acid lysis buffer. Samples
were phenol/chloroform-extracted and ethanol-precipitated. DNA
from blood and mouthwash samples was extracted by the Human
Cancer Genetics Sample Bank.
Plasmid DNA containing MCPyV DNA for use as a positive
control was obtained from Patrick S. Moore. pcDNA.MCV350(144-
3696) and pcR.MCV(3508-1796) were transformed into competent
cells using the pTargeT Vector protocol (Promega, Madison, WI).
DNA was isolated using the QIAprep Spin Miniprep Kit (Qiagen,
Valencia, CA) as per the manufacturer’s conditions. Caski cell line
DNA containing hundreds of copies of HPV for use as a positive
control was obtained from Gerard Nuovo.
MCPyV detection by PCR
Before MCPyV detection studies, the quality of the DNA was tested
by a control PCR primer set mapping to chromosome 17. Only
samples positive for the control PCR primers were included in further
analyses. We tested 298 DNAs isolated from 177 SCCs, 63 adjacent
histologically normal skin samples, 57 blood samples, and 1
mouthwash specimen from 58 study participants for MCPyV DNA
using published primer sets LT3 and VP1 (Feng et al., 2008). We
included 47 duplicate samples for which we had multiple DNA
extractions for the same tumor. PCR was carried out using 15 ng of
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input DNA using Taq DNA polymerase (Qiagen), 1 mM forward and
reverse primers, 1 Q-Solution (Qiagen), 1 PCR buffer (Qiagen),
and 500mM dNTPs (Denville Scientific, Metuchen, NJ) in a final
volume of 20 ml. Experiments included pcDNA.MCV350(144-3696)
or pcR.MCV(3508-1796) DNA as a positive control and water as a
negative control. PCR products were run on a 2% agarose gel and
visualized by ethidium bromide staining. The presence or absence of
PCR products was determined by three independent researchers. For
all samples testing positive in only one of two primer sets and an
additional 22 samples that were negative for both primer sets, we ran
radioactive PCR to increase the sensitivity of viral detection.
Radioactive PCRs were carried out in 10 ml volume using 1 mM
forward and reverse primers, 15 ng input DNA, and 0.1 ml of
alphaP32 dCTP. After amplification, products were run on a 6%
acrylamide gel, vacuum dried, and exposed to Kodak max film for
2–24 hours. For 22 samples negative by radioactive PCR and/or
regular PCR, we increased DNA input to 50 ng.
HPV detection by PCR
PCR was performed on 30 samples positive for MCPyV and 21
samples negative for the virus using 15 ng of input DNA as described
(Husnjak et al., 2000). Experiments included Caski cell line DNA as
a positive control and water as a negative control. For HPV
detection, we used MY11/MY09 (MY primers) and HPV consensus
primer sets that detect common HPV strains found in skin including
4, 5, 8, and 16.
Sequence analysis
We sequenced PCR products from 31 of the 38 samples that were
positive for the MCPyV virus and the positive control sample. PCR
products were obtained using nine different primer sets across the
viral genome. PCR products were treated with Exo/SAP-iT to remove
single-stranded DNA (USB, Cleveland, OH). Primers used for PCR
were also used for sequencing. LT3 and VP1 primers are as
published (Feng et al., 2008). Additional primers are listed in
Supplementary Table S3.
Automated sequencing of PCR products was conducted on an
ABI 3700 (Applied Biosystems, Foster City, CA) by standard
methods. Forward and reverse sequences were analyzed using
DNAstar 3.0 (http://www.dnastar.com) and were compared with the
reference sequences of the National Center for Biotechnology
Information (NCBI) Entrez Nucleotide database gb|EU375803.1
MCPyV isolate MCC350 or gb|EU375804.1 MCPyV isolate
MCC339, using the NCBI Blast program to identify mutations.
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